Literature DB >> 10150875

Use of the polymerase chain reaction in the diagnosis of ocular disease.

J M Adleberg1, C Wittwer.   

Abstract

The polymerase chain reaction is a recently introduced laboratory technique that allows for the identification of extremely small quantities of DNA. This technique offers significant advantages over more traditional methods of identifying infectious organisms causing ocular pathology. Increasing numbers of immunosuppressed and immunocompromised patients have led to the emergence of posterior segment infection from unusual and sometimes difficult to diagnose organisms. Improvements in antibiotic and antiviral therapy for specific organisms will require increasingly accurate diagnosis. Polymerase chain reaction is capable of providing this and is increasingly being used in the diagnosis of unusual vitreoretinal pathology.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 10150875     DOI: 10.1097/00055735-199506000-00014

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  4 in total

Review 1.  Diagnosis of viral and chlamydial keratoconjunctivitis: which laboratory test?

Authors:  E M Elnifro; R J Cooper; P E Klapper; A S Bailey; A B Tullo
Journal:  Br J Ophthalmol       Date:  1999-05       Impact factor: 4.638

Review 2.  Multiplex PCR: optimization and application in diagnostic virology.

Authors:  E M Elnifro; A M Ashshi; R J Cooper; P E Klapper
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

3.  Comparison of polymerase chain reaction and standard microbiological techniques in presumed bacterial corneal ulcers.

Authors:  Anita Panda; Tajinder Pal Singh; Geeta Satpathy; Meenakshi Wadhwani
Journal:  Int Ophthalmol       Date:  2014-06-24       Impact factor: 2.031

4.  Atypical acute retinal necrosis accompanied by Terson's syndrome: a case report.

Authors:  Jong Young Lee; Dong Yoon Kim; Hye Jin Lee; Jin Ho Jeong; Sung Pyo Park; Jin Young Kim
Journal:  BMC Ophthalmol       Date:  2017-12-19       Impact factor: 2.209

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.